423 related articles for article (PubMed ID: 26872057)
21. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
22. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Pavan S; Musiani D; Torchiaro E; Migliardi G; Gai M; Di Cunto F; Erriquez J; Olivero M; Di Renzo MF
Int J Cancer; 2014 Mar; 134(6):1289-99. PubMed ID: 23996744
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1.
Jin X; Pang W; Zhang Q; Huang H
J Int Med Res; 2019 Aug; 47(8):3745-3756. PubMed ID: 31117868
[TBL] [Abstract][Full Text] [Related]
24. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
25. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
26. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
27. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of eIF2α suppresses cisplatin-induced A549 cell apoptosis via p38 inhibition.
Guo L; Chen R; Ma N; Xiao H; Chen Y; Chen F; Mei J; Ding F; Zhong H
Cancer Biother Radiopharm; 2013 May; 28(4):268-73. PubMed ID: 23570372
[TBL] [Abstract][Full Text] [Related]
29. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
30. Increased HSP27 correlates with malignant biological behavior of non-small cell lung cancer and predicts patient's survival.
Sheng B; Qi C; Liu B; Lin Y; Fu T; Zeng Q
Sci Rep; 2017 Oct; 7(1):13807. PubMed ID: 29062135
[TBL] [Abstract][Full Text] [Related]
31. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
Xu L; Fu Y; Li Y; Han X
Cancer Chemother Pharmacol; 2017 Aug; 80(2):235-242. PubMed ID: 28597042
[TBL] [Abstract][Full Text] [Related]
33. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
34. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
[TBL] [Abstract][Full Text] [Related]
35. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
37. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway.
Zou A; Wu A; Luo M; Zhou C; Lu Y; Yu X
Life Sci; 2019 Oct; 235():116798. PubMed ID: 31472149
[TBL] [Abstract][Full Text] [Related]
38. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27.
Hsu HS; Lin JH; Huang WC; Hsu TW; Su K; Chiou SH; Tsai YT; Hung SC
Cancer; 2011 Apr; 117(7):1516-28. PubMed ID: 21425153
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
40. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
